NEW YORK, September 8, 2017 /PRNewswire/ --
If you want a Stock Review on ALNY, ALXN, AMRI, or BCRX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Biotech stocks have performed well in the first half of this year despite challenges like rising competition, pipeline setbacks, slowdown in growth of mature products, and generic competition for certain key drugs, as reported by Zacks. Some of the companies also raised their guidance for 2017.This morning, DailyStockTracker.com observes the following equities: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Albany Molecular Research Inc. (NASDAQ: AMRI), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc. plummeted 15.68%, ending Thursday's trading session at $72.53. The stock recorded a trading volume of 6.02 million shares, which was higher than its three months average volume of 799,330 shares. The Company's shares have surged 93.72% on an YTD basis. The stock is trading 21.90% above its 200-day moving average. Moreover, shares of the Company, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have a Relative Strength Index (RSI) of 33.58.
On September 05th, 2017, Alnylam Pharma announced that management will present a Company overview at the 15th Annual Morgan Stanley Global Healthcare Conference on September 13th, 2017, at 9:55 a.m. ET at the Grand Hyatt in New York City. A live audio webcast of the presentation will be available under the Investors section of the Company's website. Visit us today and access your complete report on ALNY for free at:
New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock declined 1.12%, closing the day at $143.50 with a total trading volume of 1.65 million shares. The Company's shares have advanced 5.48% in the past month, 39.43% in the previous three months, and 17.29% since the start of this year. The stock is trading 8.30% and 14.93% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Alexion Pharma, which develops and commercializes life-transforming therapeutic products, have an RSI of 66.24.
On September 05th, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'.
On September 05th, 2017, Alexion Pharma announced that management will present at the Morgan Stanley 15th Annual Global Healthcare Conference on September 12th, 2017, at 2:55 p.m. ET in New York. The Company will also present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on September 27th, 2017, at 9:00 a.m. ET in New York. The complimentary research report on ALXN can be accessed at:
Albany Molecular Research
On Thursday, shares in New York headquartered Albany Molecular Research Inc. ("AMRI") recorded a three months average volume of 1.27 million shares. The stock ended the day flat at $21.74. The Company's shares have advanced 0.09% in the past month, 7.78% in the previous three months, and 15.88% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.13% and 18.89%, respectively. Furthermore, shares of the Company, which provides integrated drug discovery, development, and manufacturing services primarily in the US, Europe, and Asia, have an RSI of 51.56.
On August 31st, 2017, AMRI announced the completion of its previously announced acquisition by affiliates of The Carlyle Group and affiliates of GTCR LLC. President and CEO William S. Marth will continue to lead AMRI. Register for free on DailyStockTracker.com and download the research report on AMRI at:
Durham, North Carolina headquartered BioCryst Pharmaceuticals Inc.'s stock skyrocketed 20.36%, finishing yesterday's session at $5.97. A total volume of 4.27 million shares was traded, which was above their three months average volume of 1.00 million shares. The Company's shares have advanced 32.96% in the last one month and 7.18% in the previous three months. The stock is trading above its 50-day moving average by 17.39%. Additionally, shares of BioCryst Pharma, which designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases, have an RSI of 70.07.
On August 23rd, 2017, BioCryst Pharma announced that executives from the Company are scheduled to provide a corporate summary and update regarding its clinical programs at The Robert W. Baird's 2017 Global Healthcare Conference on September 6, 2017 at 7:55 a.m. ET in New York, The Ladenburg Thalmann 2017 Healthcare Conference on September 26th, 2017 at 9:30 a.m. ET in New York and The Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017 at 3:25 p.m. ET in New York.
On September 06th, 2017, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Get free access to your research report on BCRX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.